Financials data is unavailable for this security.
View more
Year on year Coherus BioSciences Inc grew revenues 21.89% from 211.04m to 257.24m while net income improved from a loss of 291.75m to a smaller loss of 237.89m.
| Gross margin | 44.71% |
|---|---|
| Net profit margin | -0.15% |
| Operating margin | 8.44% |
| Return on assets | -0.08% |
|---|---|
| Return on equity | -- |
| Return on investment | -0.16% |
More ▼
Cash flow in USDView more
In 2023, Coherus BioSciences Inc increased its cash reserves by 61.51%, or 39.36m. Cash Flow from Investing totalled 144.64m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 174.88m for operations while cash generated from financing totalled 69.60m.
| Cash flow per share | 0.0416 |
|---|---|
| Price/Cash flow per share | 25.86 |
| Book value per share | -0.7636 |
|---|---|
| Tangible book value per share | -1.23 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.25 |
|---|---|
| Quick ratio | 1.09 |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | 1.50 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 32.78%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 96.58 |
